Jiangsu Hengrui Medicine マネジメント

マネジメント基準チェック /24

Jiangsu Hengrui Medicineの CEO はHong Bin Daiで、 May2022年に任命され、の在任期間は 2.5年です。は、会社の株式の0.027%を直接所有しており、その価値はCN¥ 81.60M 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と4.2年です。

主要情報

Hong Bin Dai

最高経営責任者

CN¥3.8m

報酬総額

CEO給与比率	n/a
CEO在任期間	2.5yrs
CEOの所有権	0.03%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	4.2yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Hong Bin Dai (48 yo)

2.5yrs

在職期間

CN¥3,821,700

報酬

Mr. Hong Bin Dai serves as General Manager of Jiangsu Hengrui Medicine Co., Ltd. since May 2022. He served as Deputy General Manager of Jiangsu Hengrui Medicine Co., Ltd.since April 2013 until May 2022 an...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Hong Bin Dai	GM & Director	2.5yrs	CN¥3.82m	0.027% CN¥ 81.6m
Jianjun Liu	Financial Director	3yrs	CN¥2.16m	データなし
Jie Ping Sun	Deputy GM & Director	no data	CN¥2.35m	0.030% CN¥ 91.1m
Lian Shan Zhang	Deputy GM & Director	12.6yrs	CN¥3.34m	0.0078% CN¥ 23.7m
Ningjun Jiang	Deputy GM & Director	1.8yrs	CN¥2.34m	データなし
Xiao Han Liu	Secretary of the Board of Directors	8.8yrs	CN¥799.10k	0.0014% CN¥ 4.2m
Su Mei Jiang	Deputy General Manager	1.8yrs	CN¥2.47m	0.023% CN¥ 70.3m
Ya Ping Shen	Deputy General Manager	11.6yrs	CN¥2.05m	0.0050% CN¥ 15.0m
Cheng Liao	Deputy General Manager	4.1yrs	CN¥2.29m	0.0026% CN¥ 7.9m
Hongsen Wang	Deputy General Manager	no data	CN¥2.14m	0.0082% CN¥ 24.9m
Feng He	Deputy General Manager	2.1yrs	CN¥2.48m	0.00020% CN¥ 607.4k
Yan Zhang	Deputy General Manager	1.8yrs	CN¥1.09m	0.0012% CN¥ 3.6m

2.8yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: 600276の経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Hong Bin Dai	GM & Director	4.8yrs	CN¥3.82m	0.027% CN¥ 81.6m
Jie Ping Sun	Deputy GM & Director	4.8yrs	CN¥2.35m	0.030% CN¥ 91.1m
Lian Shan Zhang	Deputy GM & Director	12.6yrs	CN¥3.34m	0.0078% CN¥ 23.7m
Ningjun Jiang	Deputy GM & Director	1.8yrs	CN¥2.34m	データなし
Piao Yang Sun	Chairman of the Board of Directors	21.8yrs	CN¥1.62m	データなし
Guo Qiang Xiong	Employee Representative Member of the Supervisory Committee	11.6yrs	CN¥120.00k	データなし
Kai Hong Yuan	Chairman of the Supervisory Board	1.8yrs	CN¥2.93m	0.020% CN¥ 60.9m
Jin Yun Sun	Independent Director	1.8yrs	CN¥100.00k	データなし
Qingsheng Zeng	Independent Director	1.8yrs	CN¥100.00k	データなし
Congzhao Guo	Director	4.8yrs	データなし	データなし
Jiahong Dong	Independent Director	3.5yrs	データなし	データなし
Yu Xu	Employee Representative Supervisor	2.3yrs	データなし	データなし

4.2yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: 600276の取締役会は経験豊富であると考えられます ( 4.2年の平均在任期間)。

Jiangsu Hengrui Medicine マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Jiangsu Hengrui Medicine Co., Ltd., Annual General Meeting, May 15, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 3Q 2023)

Jiangsu Hengrui Medicine Co., Ltd. Initiates Phase III Clinical Study of Cs1002/Shr-8068 (Anti-Ctla-4 Monoclonal Antibody) in Combination with Adebrelimab and Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Investor sentiment improves as stock rises 22%

Jiangsu Hengrui Medicine Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.17 in 2Q 2023)

Jiangsu Hengrui Medicine Co., Ltd. to Report First Half, 2024 Results on Aug 22, 2024

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) announces an Equity Buyback for CNY 1,200 million worth of its shares.

Jiangsu Hengrui Medicine Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Jiangsu Hengrui Medicine Co., Ltd. to Report Q1, 2024 Results on Apr 18, 2024

Investor sentiment improves as stock rises 16%

Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Commercial Launch of Vivjoa (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China

Jiangsu Hengrui Medicine Co., Ltd. to Report Fiscal Year 2023 Results on Apr 18, 2024

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 3Q 2022)

Jiangsu Hengrui Medicine Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) announces an Equity Buyback for CNY 1,200 million worth of its shares.

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.24 in 3Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.24 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.19 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.25 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.22 in 2Q 2020)

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announces on Obtaining Notice of Approval of Clinical Trial for Medicine

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.24 in 1Q 2020)

New 90-day low: CN¥89.59

Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China

New 90-day high: CN¥97.02

New 90-day low: CN¥86.17

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Jiangsu Hengrui Medicine Co., Ltd. to Report Q3, 2020 Results on Oct 20, 2020

New 90-day low: CN¥86.29

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24